Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label Study Evaluating the Safety and Effectiveness of Immunopheresis With the LW-02 Column Alone or in Combination With Paclitaxel or Atezolizumab in Removing Soluble Tumor Necrosis Factor Receptors to Treat Patients With Advanced, Non-Small Cell Lung Cancer (NSCLC)

NCT04690686 is registered in ClinicalTrials.gov with Immunicom Inc as lead sponsor.

NCT NCT04690686
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04690686 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label Study Evaluating the Safety and Effectiveness of Immunopheresis With the LW-02 Column Alone or in Combination With Paclitaxel or Atezolizumab in Removing Soluble Tumor Necrosis Factor Receptors to Treat Patients With Advanced, Non-Small Cell Lung Cancer (NSCLC)
Lead sponsor
Immunicom Inc
Phase
Phase 2
Overall status
Unknown status
Start date
October 1, 2020
Completion date
December 31, 2022
Enrollment
24 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer